Jardine Matheson (J36) H1 2026 earnings summary

Executive summary

• Achieved strong H1 2026 performance with underlying net profit up 9% year-over-year to US$735m, supported by portfolio simplification, the I-MED acquisition, and the privatization of Mandarin Oriental.

• Set clear 2030 targets: ≥9% annual TSR, ≥5% annual dividend growth, US$4bn capital recycling, and new growth pillars including healthcare.

• Significant headcount reduction (47% since 2024) and strengthening of investment team; strategic shift to control ownership in APAC.

• Ongoing corporate simplification, capital recycling, and investment in new pillars, with integration of I-MED a key focus for H2.

• Reported net profit rose 3% to US$542m compared to H1 2025.

Financial highlights

• Adjusted underlying net profit up 9% to US$735m; reported net profit up 3% to US$542m.

• Interim dividend up 8% to US$0.65/share; full-year dividend guidance raised to at least US$2.47/share (+5%).

• Parent free cash flow rose 21% to US$709m; parent net cash position at US$379m at period end.

• Net borrowings (ex-Astra FS) increased by US$906m; gearing remains low at 7%.

• Group liquidity headroom at US$12.7bn.

Outlook and guidance

• Full-year 2026 underlying earnings expected to be broadly in line with 2025, adjusted for disposals; full-year dividend guidance raised to at least US$2.47/share (+5%).

• Focus for H2 includes driving TSR, improving cash flow, portfolio simplification, and integrating I-MED.

• Guidance reflects caution due to uncertainty in Indonesia; further updates expected after Q3.

• I-MED expected to be earnings neutral in first 12 months, accretive thereafter.